Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals Inc.

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $45.00. Ac...

H.C. Wainwright Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

TD Cowen analyst Phil Nadeau maintained a Buy rating on Apellis Pharmaceuticals today and set a price target of $45.00. The company’s shares closed...

TD Cowen Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)

In a report released yesterday, Lisa Walter from RBC Capital maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $22.00. Th...

Apellis Pharmaceuticals (APLS) Receives a Hold from RBC Capital

Morgan Stanley analyst Judah Frommer maintained a Hold rating on Apellis Pharmaceuticals yesterday and set a price target of $25.00. The company’s ...

Current Quarter	$-0.39	Next Quarter	$-0.47
Current Year	$0.25	Next Year	$-1.21
QoQ Growth	-20.5%	YoY Growth	-584.0%
3Y EPS CAGR	+43.4%	Target Price	$35.39
Consensus	Buy	Upside	+80.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	APLS	$19.61	+0.36%	1.45M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	APLS	$19.61	+0.4%	1.45M
3
4
5
6

APLS

APLS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Apellis Pharmaceuticals Inc. Data in Excel

Get Apellis Pharmaceuticals Inc. Data in Excel